Integrating novel biomarkers like cystatin C into risk assessment in research settings could help facilitate personalized lifestyle or pharmacological interventions, potentially attenuating the progression of cardiorenometabolic diseases in young adulthood. This evidence concerns the gene CST3 and glycogen storage disease VI.